Humira (adalimumab) / AbbVie - LARVOL DELTA

Ustekinumab may have therapeutic effects on autoimmune thyroid disease. (PubMed, Sci Rep) - "When thyroid findings were analyzed by biologic type, ustekinumab-treated patients had the lowest AITD incidence, lower anti-thyroid peroxidase levels, and more favorable sonographic features compared with adalimumab and infliximab groups. These findings suggest that ustekinumab may have a protective or therapeutic effect on the thyroid gland and may be a potential treatment option in patients with AITD."

Journal • Endocrine Disorders • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • IL12A • IL23A

Comments on ''Long-term, real-world effectiveness of adalimumab in the treatment of hidradenitis suppurativa''. (PubMed, J Am Acad Dermatol) - "1 The study makes an important contribution to understanding the sustained efficacy of adalimumab in moderate-to-severe hidradenitis suppurativa (HS). We wish to highlight several opportunities to build upon these findings and enhance their clinical applicability."

Journal • Real-world evidence • Dermatology • Hidradenitis Suppurativa • Immunology

From juvenile idiopathic arthritis to blastic plasmacytoid dendritic cell neoplasm: A diagnostic odyssey in a 14-year-old patient (ASH 2025) - "The patient was treated with standard therapy including methotrexate and adalimumab...Novel therapeutics targeting CD123, such as tagraxofusp (SL-401), a CD123-directed cytotoxin, have shown high response rates in adult populations, yet pediatric efficacy and safety data remain limited. Other investigational agents includes, venetoclax and CD123-directed CAR-T cells... This case emphasizes the urgent need for increased awareness of BPDCN in pediatric practices, given it is bimodal distribution. Earlier diagnostic consideration in atypical autoimmune presentations and expanded access to pediatric-specific treatment protocols and clinical trials are critical keys for improving outcomes in such vulnerable population."

Clinical • Hematological Malignancies • Idiopathic Arthritis • Immunology • Lymphoma • Mucositis • Musculoskeletal Diseases • Musculoskeletal Pain • Non-Hodgkin’s Lymphoma • Orthopedics • Rheumatology • CD123 • CD4 • CLEC4C • IL3RA • NCAM1

HSV-1 infection as a rare trigger of methotrexate toxicity: A diagnostic and therapeutic challenge (ASH 2025) - "Four days earlier, she was seen in an outpatient clinic for a cold sore near the corner of her right lip and was prescribed valacyclovir 500 mg twice daily for three days for HSV infection. Her home medications included prednisone 2.5 mg, leucovorin 5 mg and methotrexate 12.5 mg weekly along with adalimumab 40 mg every 14 days...Intravenous hydrocortisone 50 mg twice daily was initiated...After a five-day course of IV steroids and a seven-day course of IV cefepime, she was discharged home on oral acyclovir to complete a 14-day total antiviral course... This case suggests that corticosteroids may be a valuable adjunct in patients with suspected methotrexate toxicity who do not respond to leucovorin. Further studies are needed to evaluate the role of corticosteroids in such cases."

Cardiovascular • Congestive Heart Failure • Diabetes • Endocrine Disorders • Febrile Neutropenia • Gastrointestinal Disorder • Heart Failure • Hematological Disorders • Herpes Simplex • Human Immunodeficiency Virus • Hypertension • Immunology • Infectious Disease • Inflammatory Arthritis • Metabolic Disorders • Nephrology • Neutropenia • Renal Disease • Rheumatoid Arthritis • Rheumatology • Scleroderma • Systemic Sclerosis • Thrombocytopenia • Type 2 Diabetes Mellitus

Risk of lymphoma with antimetabolite and biologic combinations: A pharmacovigilance analysis using the FDA adverse event reporting system database (ASH 2025) - "Our study compared combinations of antimetabolites—such asmethotrexate (MTX), mercaptopurine (6-MP), and azathioprine (AZA)—with anti-TNF agents includinginfliximab, adalimumab, certolizumab, and golimumab, to determine which regimens were most stronglyassociated with lymphoma. Clinicians should carefully weigh the risks and benefits of combination immunosuppressivetherapy, especially when prescribing infliximab with MTX or 6-MP, given the observed synergistic increasein risk for lymphoma."

Adverse events • Hematological Malignancies • Immunology • Lymphoma • ROR1

Interleukin-12 and TNFα signaling drives parallel evolution of independent leukemic clones in JAK2V617F mutant myeloproliferative neoplasms (ASH 2025) - "To examine this finding in a more translationally relevant system, weadministered murine biosimilars of TNFα and IL-12 monoclonal neutralizing antibodies(adalimumab/ustekinumab respectively) into our chimeric systems and the human agonist into our PDXsystem...Genetic and pharmacological inhibition of IL-12and TNFα resulted in both functional and molecular rescue of this phenotype. We aim to leverage thesefindings to enhance disease surveillance in MPN populations and identify candidates for potentialinterventional therapy."

Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myeloproliferative Neoplasm • CD34 • ELANE • HOXA10 • IL12A • JAK2 • KIT • MECOM • TET2 • TNFA • TP53

Aged B cells as a candidate cell of origin for diffuse large B cell lymphoma: A multi-modal analysis of somatic mutation, clonality, and transcriptional programs (ASH 2025) - "To establish a biological connection between ABCsand DLBCL, we analyzed paired blood and tumor samples to identify shared mutations and CDR3 clones.Longitudinal immune monitoring in autoimmune patients treated with biologic agents (adalimumab,belimumab, etanercept) was used to assess treatment-related changes in ABC dynamics. Our findings implicate ABCs as a likely reservoir of lymphoma-initiating clones and a candidate cell oforigin for DLBCL. The enrichment of AID-driven mutations, clonal dominance, and overlapping betweenABC and tumor clones supports a model in which aberrant persistence and ongoing mutagenesis in ABCspromote lymphomagenesis. This work establishes a framework for mutation-informed MRD surveillanceand highlights the clinical relevance of ABC biology across both AI and B cell malignancy."

B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Immunology • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • AICDA • ARID1A • CD14 • ITGAX • ITGB2 • KMT2D • PRDM1 • ZEB2

Anti-CD19 chimeric antigen receptor T-cell therapy for patients with non-Hodgkin's lymphoma and concurrent autoimmune disease (ASH 2025) - "methotrexate, hydroxychloroquine (HCQ),azathioprine); 9 required biologic/targeted DMARD (ex. adalimumab, etanercept, risankizumab,infliximab, rituximab).DMARDs were weaned prior to CART however 9 pts (37.5%) remained on AID tx at the time of cellcollection, including HCQ (n=4), sulfasalazine/mesalamine (n=2), and 1 each of prednisone, colestipol,sulfasalazine, and apremilast... In this single center study of pts receiving CART for NHL we found no difference in responserates nor survival outcomes in pts with or without AID and therefore propose that AID should notpreclude the use of CART. Lower severity of ICANS was seen in AID pts, though additional study withlarger cohorts is required. The majority of pts were able to taper off AID tx prior to CART, while HCQ wasable to be safely continued throughout CART collection with no apparent effect on CART efficacy."

CAR T-Cell Therapy • Clinical • Ankylosing Spondylitis • B Cell Non-Hodgkin Lymphoma • CNS Disorders • Dermatology • Dermatomyositis • Gastroenterology • Hematological Disorders • Hematological Malignancies • Immunology • Inflammatory Arthritis • Lymphoma • Myasthenia Gravis • Myositis • Non-Hodgkin’s Lymphoma • Psoriasis • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies

P111 A multicentre service evaluation highlighting the variable off-label prescribing practice of spironolactone in the management of hidradenitis suppurativa: the need for evidence-based guidelines. (PubMed, Br J Dermatol) - "Most were prescribed spironolactone as an adjunct to their existing management, including oral antibiotics, metformin and adalimumab. We conclude that there is significant variability in patient selection, monitoring and prescribing practices of spironolactone for HS across these UK sites. With a view to addressing the uncertainties outlined in the James Lind Priority Setting Partnerships for HS, we propose that a multicentre randomized controlled trial is needed to inform the evidence base and to produce clear UK guidelines on treatment with spironolactone in HS."

Journal • Retrospective data • Dermatology • Hidradenitis Suppurativa • Immunology • Inflammation • Pain • Xerostomia

P162 Evaluation of a remote tertiary hub-and-spoke model for the approval of high-cost drugs in medical dermatology. (PubMed, Br J Dermatol) - "Eighteen referrals were for HS: 11 for use of adalimumab and 7 for secukinumab. With HS affecting > 200 000 people in the UK, and more therapies being approved for use, it is conceivable that local decision making may become more appropriate, and these results suggest clinicians feel confident making such decisions. Tertiary discussion for rituximab use seemed to be deemed appropriate by users."

Journal • Dermatology • Hidradenitis Suppurativa • Immunology • Pemphigus Vulgaris • Psoriasis

BI32 Something fishy about that ulcer: a leg ulcer on an immunocompromised scuba diver. (PubMed, Br J Dermatol) - "He had a history of psoriatic arthritis, on dual immunosuppression for the past 5 years with methotrexate and adalimumab...He received penicillin antibiotics, topical steroids and mupirocin cream from his general practitioner. He was switched from adalimumab to infliximab for a presumed diagnosis of pyoderma gangrenosum by his treating rheumatology team...His immunosuppression is on hold, both ulcerated lesions continue to slowly enlarge and he remains under close review. This case demonstrates the importance of a full medical and social history, including hobbies and travel, in all patients on immunosuppressive therapy, as they are at risk of atypical infections and presentations."

Journal • Hepatitis B • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Oncology • Pain • Psoriasis • Psoriatic Arthritis • Pyoderma Gangrenosum • Rheumatology • Seronegative Spondyloarthropathies • Varicella Zoster • IFNG

P121 Treatment with semaglutide improves the systemic inflammatory burden associated with hidradenitis suppurativa. (PubMed, Br J Dermatol) - "The majority of patients (n = 54) had Hurley stage II disease, with 10 patients classified as Hurley stage III and 5 as Hurley stage I. Twenty-two patients were established on adalimumab with two on infliximab. Other biologics prescribed alongside semaglutide included brodalumab (n = 8) and secukinumab (n = 1). Nineteen patients were coprescribed metformin, and for 16 patients rescue antibiotics including rifampicin and clindamycin...Semaglutide can improve not only metabolic control, weight, flare frequency and quality of life, but also systemic inflammation and thus health outcomes (Lyons et al.). Although our findings did not reach statistical significance, the consistent trends observed in inflammatory markers and the established efficacy of semaglutide in weight loss and metabolic improvement suggest that it can enhance health outcomes for this patient population."

Journal • Retrospective data • Dermatology • Genetic Disorders • Hidradenitis Suppurativa • Immunology • Inflammation • Metabolic Disorders • Obesity • Systemic Inflammatory Response Syndrome

SG14 Homozygous pathogenic variant in transgradient palmoplantar keratoderma: causative, contributory or irrelevant? (PubMed, Br J Dermatol) - "He is currently managed on acitretin 25 mg once daily and psoralen plus ultraviolet A. Acitretin at 50 mg alone was effective but was discontinued due to side-effects. Previous treatment with secukinumab and adalimumab was not beneficial...However, 10% of individuals with European ancestry are heterozygous carriers of loss-of-function variants in the FLG gene. This high carrier frequency in the general population suggests that FLG may be only a contributing factor, and other variants or environmental factors are important in the manifestation of PPK, if FLG variants are found in so many unaffected individuals."

Journal • Asthma • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pulmonary Disease • Respiratory Diseases • Vitiligo • FLG

P003 Predictors of differential treatment response between adalimumab and methotrexate in psoriasis: a causal forest analysis of the British Association of Dermatologists Biologics and Immunomodulators Register. (PubMed, Br J Dermatol) - "Factors such as age, sex, baseline PASI, weight and number of comorbidities are associated with differential treatment responses when prescribing adalimumab or methotrexate. These findings provide a data-driven framework to support personalized treatment decisions in clinical practice."

Clinical • Journal • Dermatology • Immunology • Psoriasis

BG03 Biologics for psoriasis in the older patient: profiles, pitfalls and practicalities. (PubMed, Br J Dermatol) - "Hence, as the prescription of conventional treatments such as methotrexate or ciclosporin can be frustrated by drug interactions or contraindications, the use of biologics could actually be the most appropriate therapeutic avenue to pursue...found ustekinumab or adalimumab to be effective but noted an increased incidence of side-effects (Momose M, Asahina A, Hayashi M et al...However, the presence of psoriatic arthritis in the older group was more likely to have influenced use of the biologic. In conclusion, it is apparent that indications for the prescription of biologics in patients in their seventh decade or more should be the same as in younger cases, but in view of comorbidities and concurrent drug use, there needs to be extra vigilance for side-effects and other complications."

Journal • Review • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

P089 Efficacy of tofacitinib in cases of moderate-to-severe (stage 2 and stage 3) hidradenitis suppurativa: a pilot study. (PubMed, Br J Dermatol) - "Treatment options are limited, and existing therapies like adalimumab and secukinumab show inconsistent results. In conclusion, tofacitinib showed significant potential in treating moderate-to-severe HS, improving disease severity, quality of life and associated inflammation. These promising findings highlight the need for more extensive trials with controls to confirm its safety and efficacy."

Journal • Dermatology • Fibrosis • Hidradenitis Suppurativa • Immunology • Inflammation • Pain • IL6

P088 Janus kinase inhibitor treatment in coexisting atopic dermatitis and irritable bowel disease: real-world experience and therapeutic outcomes. (PubMed, Br J Dermatol) - "Despite the apparent efficacy treating IBD in this series, only two of seven patients (29%) achieved satisfactory cutaneous response to JAKi monotherapy, contrasting with established efficacy data in isolated AD. These findings raise questions about underlying disease mechanisms in this phenotype, warranting further investigation.TableTreatment of seven patients with atopic dermatitis (AD) and irritable bowel disease (IBD) with Janus kinase inhibitors (JAKis)Age (years)Primary indicationBefore JAKi treatmentOn JAKi treatmentDisease statusAD treatmentIBD treatmentJAKi therapyOutcomes50ADEASI 54; UC controlledNoneGuselkumab (stopped)Upadacitinib 24 months (ongoing)EASI 75 achieved (5.1); UC remission22AD, CDEASI 41; CD activeMethotrexate (stopped)Infliximab (stopped)Upadacitinib 4 months (ongoing)EASI 75 achieved (7.4); CD remission29ADEASI 13; UC controlledNoneAZA, allopurinol (stopped)Upadacitinib 8 months (ongoing)EASI 10.3; added methotrexate (6 months), switched to..."

Journal • Real-world evidence • Alopecia • Atopic Dermatitis • Crohn's disease • Dermatitis • Dermatology • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Herpes Zoster • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • Varicella Zoster

P024 Anakinra for recalcitrant pyoderma gangrenosum with Achilles tendon exposure. (PubMed, Br J Dermatol) - "He was commenced on ciclosporin with initial improvement, but uptitration was limited to 3 mg kg-1 per day due to the development of significant renal impairment, which required medical admission. Treatment was switched to adalimumab fortnightly...After 14 months of treatment, all areas of ulceration are almost completely healed with one area of mild overgranulation, currently being treated with topical clobetasol propionate...It also reveals the importance of regular wound care and lower-limb compression in the setting of ulcers at this site. Anakinra represents a potentially effective treatment option with a relatively low side-effect profile."

Journal • Atrial Fibrillation • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Dermatology • Diabetes • Gastroenterology • Gastrointestinal Disorder • Heart Failure • Hypertension • Immunology • Inflammatory Bowel Disease • Metabolic Disorders • Nephrology • Oncology • Pain • Pyoderma Gangrenosum • Renal Disease • Thrombosis • Type 2 Diabetes Mellitus • Vasculitis • Venous Ulcer

P119 Serum complement, B cells and T cells as markers of treatment response in those treated with adalimumab and clindamycin-rifampicin for hidradenitis suppurativa: a pilot study. (PubMed, Br J Dermatol) - "Our patient numbers are small. If these findings are validated in a larger cohort this would begin to allow, for the first time, the personalization of treatment for HS."

Biomarker • Journal • Dermatology • Hidradenitis Suppurativa • Immunology • Inflammation • CRP

O07 Serious infection risk with systemic treatments for psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). (PubMed, Br J Dermatol) - "Inclusion criteria were adults who received at least one of the biologics, apremilast or conventional nonbiologics (acitretin, ciclosporin and methotrexate) for ≥ 6 months. All biologics licensed for psoriasis were analysed except for infliximab, which had higher prescription criteria...The certolizumab group had a low mean age of 37.4 years (SD 10.3), the ustekinumab group had a significantly longer median treatment duration of over 4 years (IQR 1.83-6.73), and more patients in the ixekizumab (42.6%) and certolizumab (40.6%) groups had concomitant psoriatic arthritis...IRs (95% CIs) of other tumour necrosis factor-α inhibitors were 15.7 (14.5-17.1) for adalimumab and 16.7 (13.8-20.0) for etanercept. For interleukin-17 inhibitors the IRs (95% CIs) were 18.4 (15.9-21.2) for secukinumab, 7.63 (0.92-27.6) for bimekizumab, 14.5 (7.73-24.8) for brodalumab and 18.5 (14.0-24.0) for ixekizumab. For interleukin-23 inhibitors the IRs (95% CIs) were 13.5 (9.97-17.8) for guselkumab,..."

Journal • Observational data • Dermatology • Immunology • Infectious Disease • Inflammatory Arthritis • Oncology • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL12A • IL17A

BH18 A rare case of nail sarcoidosis presenting as an ulcerated nail tumour in a Afro-Caribbean patient. (PubMed, Br J Dermatol) - "At the time of referral to dermatology, his scrotal and skeletal sarcoidosis had not been fully controlled on single-agent methotrexate 20 mg weekly, so adalimumab 40 mg fortnightly had been added with subsequent discontinuation of methotrexate after 2 months of dual therapy...Plaquenil 200 mg twice daily was added, with a marked improvement in both his cutaneous and nail sarcoid. We present this interesting case to highlight the awareness of nail sarcoid being a possible cause of a destructive nail process in this population group, with the aim of increasing awareness of nail sarcoidosis and the extent of possible systemic involvement. We highlight the usefulness of nailbed biopsy and X-ray of the hands in this case, in addition to the importance of thorough systemic evaluation and investigations where appropriate in sarcoidosis."

Journal • Dermatology • Immunology • Melanoma • Oncology • Rheumatology • Sarcoidosis • Solid Tumor

AI02 (P002) Predicting psoriasis biologic drug discontinuation: an explainable machine learning approach applying British Association of Dermatologists Biologics and Immunomodulators Register data. (PubMed, Br J Dermatol) - "Within the discontinuation cohort, adalimumab (originator and biosimilars, 57%) was most prescribed...In conclusion, AdaBoost represents an explainable, ML model with potential clinical utility to predict treatment outcomes of patients with psoriasis using real-world registry data. Future work will investigate discontinuation risk across a range of individual biologic therapies."

Journal • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

P091 Posterior reversible encephalopathy syndrome (PRES) presenting in a patient with psoriasis receiving ustekinumab. (PubMed, Br J Dermatol) - P3 | "Prochlorperazine 5 mg three times daily and amlodipine 10 mg once daily were commenced and ustekinumab suspended...PRES has been described in patients using adalimumab, infliximab and ustekinumab, most commonly in the context of inflammatory bowel disease...However, it is important that clinicians are aware of this rare debilitating neurological adverse event, so prompt withdrawal of possible triggers including biologic agents can be made to facilitate neurological recovery. The half-life of ustekinumab is problematic for prompt withdrawal and there remain questions regarding ongoing management of the patient's inflammatory dermatosis and arthritis, as case reports document worsening of PRES on reintroduction of traditional immunosuppressive systemic agents."

Journal • Cardiovascular • CNS Disorders • Dermatology • Epilepsy • Gastroenterology • Gastrointestinal Disorder • Hypertension • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Pain • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

P114 Efficacy and safety of oral Janus kinase, tyrosine kinase 2 and phosphodiesterase 4 inhibitors in the treatment of chronic plaque psoriasis: a network meta-analysis. (PubMed, Br J Dermatol) - "After 16-24 weeks of treatment, tofacitinib and deucravacitinib had the highest efficacy, followed by apremilast, orismilast, upadacitinib and brepocitinib. Zasocitinib, a new highly selective allosteric TYK2 inhibitor, has recently demonstrated promising efficacy in the treatment of psoriasis, with 33% of patients achieving PASI 100 (complete clearance of psoriasis lesions) after just 12 weeks of treatment. In conclusion, oral TYK2 inhibitors have shown efficacy in the treatment of chronic plaque psoriasis comparable with adalimumab, with newer agents demonstrating enhanced effectiveness and surpassing PDE-4 inhibitors in therapeutic outcomes. JAK inhibitors, particularly tofacitinib, exhibit comparable efficacy to some TYK2 and PDE-4 inhibitors."

Clinical • Journal • Retrospective data • Review • Dermatology • Immunology • Psoriasis • TYK2

O05 A retrospective review of cases of psoriasis requiring discontinuation of biologic therapy from 2007 to 2024 in a multisite NHS trust. (PubMed, Br J Dermatol) - "Concurrent systemic immunosuppression (methotrexate or ciclosporin) was prescribed in 21% (n = 31)...The biologics with most interventions were adalimumab or biosimilars (n = 102: Humira n = 39, Idacio n = 30, Hyrimoz n = 23, Amgevita n = 10), ustekinumab (n = 39), secukinumab (n = 35), guselkumab (n = 13) and certolizumab (n = 11)...The main blood abnormality was positive tuberculosis ELISpot assay (interferon-γ release assay) (n = 6: Humira n = 2; and Idacio, ustekinumab, etanercept and risankizumab n = 1 each). Other abnormalities included leucocytosis in sepsis (n = 2; ustekinumab, secukinumab), neutropenia (n = 1; Hyrimoz), raised alanine aminotransferase (n = 1; Humira) and raised fetal calprotectin (n = 1; Ixekizumab)...Blood abnormalities requiring treatment intervention were infrequent, most commonly positive tuberculosis testing. Our findings support reducing blood monitoring of..."

Journal • Retrospective data • Atopic Dermatitis • Dermatology • Diabetes • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hepatology • Hidradenitis Suppurativa • Immunology • Infectious Disease • Inflammatory Arthritis • Inflammatory Bowel Disease • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Neutropenia • Pain • Psoriasis • Psoriatic Arthritis • Pulmonary Disease • Respiratory Diseases • Rheumatology • Septic Shock • Seronegative Spondyloarthropathies • Tuberculosis • Type 2 Diabetes Mellitus • Ulcerative Colitis • Urticaria • IFNG